Arrowhead Pharmaceuticals Secures FDA Priority Review Voucher for Plozasiran Expansion — Arrowhead Pharmaceuticals, Inc.

Event summary

Arrowhead Pharmaceuticals acquired an FDA Rare Pediatric Disease Priority Review Voucher (PRV) from an undisclosed third party.
The PRV will be used for the upcoming sNDA submission for plozasiran to treat severe hypertriglyceridemia (sHTG), expected before year-end 2026.
Plozasiran is already approved as REDEMPLO® for familial chylomicronemia syndrome (FCS), a severe form of sHTG.
The PRV reduces FDA review time from 10 months to 6 months, accelerating potential approval.

The big picture

Arrowhead's acquisition of an FDA Priority Review Voucher underscores its strategic focus on accelerating access to treatments for severe hypertriglyceridemia, a condition with limited therapeutic options. This move aligns with broader industry trends toward expedited regulatory pathways for rare disease therapies, particularly those addressing high unmet medical needs. The deal also highlights the growing importance of PRVs as strategic assets in biopharmaceutical development.

What we're watching

Regulatory Efficiency: How the PRV acquisition will impact the timeline for plozasiran's expanded approval in sHTG.
Market Differentiation: Whether Arrowhead can leverage this acceleration to strengthen its position against competitors in triglyceride management.
Commercial Strategy: The pace at which Arrowhead can integrate the PRV into its broader commercialization plans for REDEMPLO® beyond FCS.